The U.S. Department of Health and Human Services (HHS) posted the General and Targeted Distribution Post-Payment Notice of Reporting Requirements on the Provider Relief Fund (PRF), which aims to inform those who have received one or more payments from the PRF of the upcoming timeline for future reporting requirements.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The Centers for Medicare & Medicaid Services (CMS) published the Open Payments Program Year 2019 data, along with newly submitted and updated payment records from previous program years.
The Centers for Medicare & Medicaid Services (CMS) announced flexibilities for clinicians participating in the 2020 Quality Payment Program (QPP) Merit-based Incentive Payment System (MIPS) who have been impacted by the COVID-19 Public Health Emergency (PHE). Affected clinicians may submit an Extreme & Uncontrollable Circumstances Application to reweight any MIPS performance categories or may apply for the MIPS Promoting Interoperability Performance Category Hardship Exception.
The Association for Clinical Oncology (ASCO) recently sent a letter to House and Senate leadership urging their support for policies to increase diversity in clinical trials, including the CLINICAL TREATMENT Act (H.R. 913), in a future COVID-19 response package.
A new study in JCO Oncology Practice (JCO OP) shows that using clinical pathways in an oncology-specific alternative payment model (APM) can help reduce the cost of cancer care.
WHAT: Clinical trials often provide patients with life-threatening conditions the best - perhaps only - treatment option for their condition. However, unlike Medicare and private and commercial payers, Medicaid is not federally required to cover routine care costs (like physician visits and laboratory studies) for patients on clinical trials. Without the guarantee of coverage, many Medicaid beneficiaries do not have the latest technological and scientific advancements as a treatment option.
The American Society of Clinical Oncology (ASCO) released a position statement, “Block Grants in Medicaid & Their Impact on Cancer Care,” summarizing the Society’s concerns about the potential negative impact that recent proposals to establish annual limits on federal funding for Medicaid—or block grants—could have on patients with cancer. The statement urges state and federal policymakers not to enact, apply for, or advance any proposals to establish block grants for Medicaid programs.
The Georgia Society of Clinical Oncology (GASCO) and the American Society of Clinical Oncology (ASCO) sent a letter to Georgia Governor Brian Kemp with concerns about a proposal to partially expand Medicaid in the state. Known as an 1115 waiver, the proposal would extend Medicaid coverage to merely 89,000 of the 1.5 million uninsured Georgians, while imposing work requirements and other restrictions on the program.
The Tennessee Oncology Practice Society (TOPS) and the American Society of Clinical Oncology (ASCO) sent a letter to the Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma, outlining concerns about Tennessee’s proposal to transition its current Medicaid program to a block grant approach.